Table 2.

MACE within 30 days in patients in rule-out zone for cohorts 1 and 2.

Number in rule-out zone, (%; 95% CI)NPV (95% CI)Sensitivity (95% CI)
Cohort 1Cohort 2Cohort 1Cohort 2Cohort 1Cohort 2
hs-cTnT
    2h-ADP0/496 (0%; 0.0%–0.9%)3/469 (0.6%; 0.2%–2.0%)100% (99.3%–100%)99.4% (98.1%–99.9%)100% (98.5%–100%)94.7% (90.4%–97.4%)
    2-h algorithm5/873 (0.6%; 0.2%–1.4%)9/780 (1.2%; 0.6%–2.2%)99.4% (98.7%–99.8%)98.8% (97.8%–99.5%)97.9% (95.2%–99.3%)81.9% (75.7%–87.1%)
hs-cTnI
    2h-ADP1/511 (0.2%; 0.0%–1.3%)2/492 (0.4%; 0.1%–1.6%)99.8% (98.8%–100%)99.6% (98.5%–100%)99.6% (97.7%–100%)94.1% (89.8%–97.0%)
2-h algorithm3/757 (0.4%; 0.1%–1.3%)7/698 (1%; 0.4%–2.2%)99.6% (98.9%–99.9%)99.0% (97.9%–99.6%)98.7% (96.4%–99.7%)85.6% (79.8%–90.3%)